諾和諾德的 CagriSema 2.4 毫克/2.4 毫克在 REIMAGINE 計畫的多項研究中均顯示出顯著降低 HbA1c 和體重的效果。
美國新澤西州普萊恩斯伯勒和丹麥巴格斯沃斯，2026 年 6 月 7 日 /PRNewswire/ -- 諾和諾德 REIMAGINE 1-3 試驗的 3 期結果於今日公佈，結果顯示，2 型糖尿病 (T2D) 成年患者的 HbA1c 和體重顯著降低。
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Haeufig gestellte Fragen
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
